Needham & Company Starts �terna Zentaris (AEZS) at Buy; Three Late-Stage Trials, Three Partners, and Three Potential Stock Catalysts

May 31, 2011 7:50 AM EDT Send to a Friend
Get Alerts AEZS Hot Sheet
Price: $0.61 --0%

Rating Summary:
    4 Buy, 7 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 9 | Down: 10 | New: 35
Trade AEZS Now!
Join SI Premium – FREE
Needham & Company initiates coverage on Æterna Zentaris (NASDAQ: AEZS) with a Buy.

Needham analyst says, "We believe the time is right for investors interested in small-cap biotech stocks to turn increasing attention to AEZS, given the Company’s pipeline progress in targeted cancer therapeutics as well as expected near-term events. We are initiating coverage with a Buy rating and a price target of $5: our valuation thesis includes a sum-of-the-parts calculation and comparables analysis...We believe the Company’s solid science platform has matured and includes perifosine (Phase 3 underway), AEZS-108 (Phase 3 planned), and AEZS-130 (Phase 3 underway)."

For more ratings news on Æterna Zentaris click here and for the rating history of Æterna Zentaris click here.

Shares of Æterna Zentaris closed at $2.37 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Hot New Coverage, New Coverage

Related Entities

Needham & Company

Comments

Perifosine and AEZS
DR JAYSON ZORTMAN on 2011-05-31 14:36:40
Mark as Spam | Reply to this comment

Was wondering when the financial world would see value of this company!! Think $5 is conservative.


Add Your Comment